Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Ann Neurol. 2019 Jul 30;86(3):384–394. doi: 10.1002/ana.25545

Figure 2.

Figure 2.

Plasma sST2 is associated with outcome and mortality in the Boston cohort. A) ROC analysis finds early sST2 to be a predictor of poor outcome (mRS 3–6) at 90 days (C statistic = 0.724, 95% CI 0.620–0.827, Youden’s cutpoint 80.8ng/mL, p < 0.001). B) Similar results are observed for mortality, where early sST2 is again a predictor of outcome (C statistic = 0.788, 95% CI 0.681–0.896, Youden cut point: 91.3ng/ml, p = 0.002). C) Kaplan Meier analysis of patients with high versus low sST2 (dichotomized based on the median level at the first timepoint) found those with high sST2 to have a significantly higher rate of death (Figure 2D, p < 0.001).